Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- Kissei Takes Over Marizev Marketing Authorization from MSD Japan
September 25, 2024
- Daiichi Sankyo Releases JN.1-Tailored COVID Jab Daichirona
September 25, 2024
- Astellas’ Gastric Cancer Drug Vyloy Wins European Approval
September 25, 2024
- Otsuka Wraps Up Buyout of Jnana Therapeutics
September 25, 2024
- NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
- Japan’s 1st CGP Assay for Blood Cancer Approved: Otsuka
September 24, 2024
- Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing
September 24, 2024
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Xofluza Cuts Risk of Flu Transmission in Households: PIII Data
September 20, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
- Viatris to Discontinue Nesp Biosimilar after Global Business Sell-Off
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
- AnGes’s Gene Therapy Collategene Gets FDA Breakthrough Therapy Tag
September 19, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- J-TEC Prepping to File for Allogeneic Cultured Epidermis, Eyes Overseas Export
September 19, 2024
- Enhertu Effective in HER2 Breast Cancer with Brain Metastases
September 18, 2024
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…